% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • fezziwig2008 fezziwig2008 Oct 18, 2013 1:18 PM Flag

    Roche Reported MabThera Revenues-$4B for 9mos exUS- So 5% of 5-6B Ann is $100-150M @ 50% conversion rate

    AS the "ALL-IV" Biosimilars Threaten, More conversion from IV to SC MabThera- GA101 won't be ready to defend #1 Indication NHL for Years-all left to SC.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • NOW Big Preference Study being done by Roche- MabThera SC vs IV- as with Herceptin and HyQvia- SC is the future

    • haven't mentioned HTI-501 much or lately, which had positive-looking early results shared on June 29th for their current phase 1/2 cellulite study. I think it is wholly owned by halo and if I remember correctly from some article, the estimated market for cellulite alone dwarfs most or all of the other drugs halo is partnered with. That is not to even mention how HTI-501 could also help with other conditions such as aesthetic and connective tissue disorders like keloid and hypertrophic scarring, localized scleroderma, frozen shoulder syndrome and Dupuytren's contracture.

      I bring this up since it seems to me HTI-501 is the often overlooked giant in terms of potential future revenues.

      • 1 Reply to lucidguide
      • yes I think it will have revenues in excess of Botox ($2B) when approved- But that's a few years off- Next interim report next Spring at 10th annual cosmetic derm world meeting- the reason it will exceed Botox is that it's MUCH easier to inject- Botox is a poison- it travels and can cause a droopy eyelid or a Bells Palsy picture for Months if not done right- HTI-501 is shot into fat and doesn't travel- ph Neutralized quickly.

    • My respects. Hope you will recast the thoughts above in language suitable for lay persons such as myself.
      Thanks and Be Well

      Sentiment: Hold

12.08+0.18(+1.51%)Sep 30 4:00 PMEDT